Evidence map›Paper›PMID 35527776›Full record

ReviewOncology letters2022

Role of

Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Pan-Cancer Computational Analysis of RKIP (International journal of molecular sciences · 2025
    Article
  2. Review
  3. Review
  4. Case Report: Response toFrontiers in oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wen ZhouDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Lu-Da YanDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Zhi-Qiong YuDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Na LiDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Yong-Hua YangDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Meng WangDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Yuan-Yuan ChenDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Meng-Xia MaoDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Xiao-Chun PengLaboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Jun CaiDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, P.R. China.
Yangtze University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase

Indexed as

anaplastic lymphoma kinase-positivedrug resistancenon-small cell lung cancerSTK11targeted therapies

Identifiers

PMID35527776
PMCPMC9073580
OpenAlexW4223897505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.